GSK (LON:GSK) Insider Buys £64,173.54 in Stock

GSK plc (LON:GSK) insider Vishal Sikka bought 1,266 shares of GSK stock in a transaction dated Monday, June 22nd. The stock was purchased at an average price of GBX 5,069 per share, for a total transaction of £64,173.54.

GSK Price Performance

Shares of GSK traded up GBX 35.50 during trading hours on Tuesday, hitting GBX 1,960. The stock had a trading volume of 27,888,139 shares, compared to its average volume of 8,764,782. The stock has a market capitalization of £78.60 billion, a price-to-earnings ratio of 13.79, a P/E/G ratio of 1.24 and a beta of 0.29. The company has a debt-to-equity ratio of 106.74, a current ratio of 0.79 and a quick ratio of 0.73. The company’s fifty day moving average is GBX 1,955.63 and its two-hundred day moving average is GBX 1,966.35. GSK plc has a 52 week low of GBX 1,288.61 and a 52 week high of GBX 2,282.

GSK (LON:GSK) last issued its quarterly earnings data on Wednesday, April 29th. The company reported GBX 46.50 earnings per share for the quarter. The firm had revenue of GBX 762.90 billion for the quarter. GSK had a net margin of 17.78% and a return on equity of 35.78%. On average, analysts anticipate that GSK plc will post 175.980975 EPS for the current year.

Analyst Upgrades and Downgrades

A number of analysts recently weighed in on GSK shares. Berenberg Bank reissued a “hold” rating and issued a GBX 2,000 price target on shares of GSK in a report on Thursday, March 26th. Jefferies Financial Group reaffirmed a “buy” rating and set a GBX 2,500 price objective on shares of GSK in a report on Thursday, May 28th. Shore Capital Group reissued a “buy” rating on shares of GSK in a research note on Wednesday, March 25th. Deutsche Bank Aktiengesellschaft restated a “hold” rating and set a GBX 1,900 target price on shares of GSK in a research report on Monday, June 8th. Finally, Citigroup cut their price target on GSK from GBX 2,250 to GBX 2,100 and set a “neutral” rating on the stock in a research note on Wednesday, May 6th. Two equities research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of GBX 2,034.29.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections.